On Wednesday, the FDA granted 510(k) clearance to Vivos Therapeutics, Inc.’s (NASDAQ:VVOS) flagship oral medical device, ...

Shares of Vivos Therapeutics (NASDAQ:VVOS) climbed on Wednesday after MedTech announced the FDA's 510(k) clearance for its ...

Vivos is poised to disrupt the very significant pediatric obstructive sleep apnea (OSA) market with new FDA clearance and new strategic marketing ...

Vivos Therapeutics shares rose on Wednesday after the company said its oral medical device for pediatric sleep apnea and snoring received 510(k) clearance from the Food and Drug Administration. Shares ...

Vivos is poised to disrupt the very significant pediatric obstructive sleep apnea (OSA) market with new FDA clearance and new strategic marketing and distribution model Vivos' DNA appliance now ...

Vivos Therapeutics (NASDAQ: VVOS), a leading medical-device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related ...

The gross proceeds to the Company from the offering are expected to be approximately $4.3 million, before deducting the placement agent's fees and other offering expenses payable by the Company. The ...

Vivos Therapeutics (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related ...

Vivos Therapeutics is a pioneering medical device and technology company focused on addressing sleep-related breathing disorders (SRBDs), particularly obstructive sleep apnea (OSA). Their flagship ...

Winners of the 2024 Lasker Awards include researchers who discovered and developed GLP-1 agonists, infectious disease ...

Vivos Therapeutics shares surged 47.50% to close at $4.13, after hitting an intraday high of $5.95 and a low of $3.02. The ...

"I think a year-end price target for us is $2,750. And about a 12 to 15-month price target is $3,000," Blue Line Futures chief market strategist Phil Streible says about gold prices (GC=F). "And it's ...